Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Myung-Ju AhnByoung Chul ChoEnriqueta FelipIppokratis KorantzisKadoaki OhashiMargarita MajemOscar Juan VidalSabin HandzhievHiroki IzumiJong-Seok LeeRafal DziadziuszkoJürgen WolfFiona BlackhallMartin ReckJean Bustamante AlvarezHorst-Dieter HummelAnne-Marie C DingemansJacob SandsHiroaki AkamatsuTaofeek K OwonikokoSuresh S RamalingamHossein BorghaeiMelissa L JohnsonShuang HuangSujoy MukherjeeMukul MinochaTony JiangPablo MartinezErik S AndersonLuis Paz-Aresnull nullPublished in: The New England journal of medicine (2023)
Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, NCT05060016.).
Keyphrases